Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 704)
Posted On: 11/06/2024 6:19:31 AM
Post# of 153903
Posted By: My69z
MD/GSK/AISC:

2013:
Oncology Clinical and Translational Consortium

** notice MD Anderson

https://www.gsk.com/en-gb/media/press-release...h-centres/
___
Jan. 2020:
https://www.ncc.go.jp/en/information/2020/0820/index.html
___

Jump to this:

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have collaborated on several cancer research projects, including:

Therapeutic antibodies:
MD Anderson and GSK developed and licensed therapeutic antibodies that target the OX40 receptor on T cells. The antibodies promote the immune system's attack on cancer.

Immunotherapy drug:
GSK worked with MD Anderson's Moon Shots Program to develop a new immunotherapy drug and clinical trial.

MD Anderson's Institute for Applied Cancer Science (IACS) has partnered with biopharmaceutical companies to develop drugs.
____

Follow IACS:

The Institute for Applied Cancer Science (IACS) is a collaboration between GlaxoSmithKline (GSK) and the University of Texas MD Anderson Cancer Center. The IACS is a patient-focused research center that aims to develop new small-molecule drugs to treat cancer. The IACS works with a team of scientists and physicians to design drugs that address the most pressing needs of patients.

___

Using this approach, IACS works closely with the Moon Shots® and platforms to advance new targeted therapies to patients quickly, safely and effectively.

https://www.mdanderson.org/cancermoonshots/re...ience.html
___

From White House website:

In February 2022, President Biden announced a reignition of the Cancer Moonshot, with a call to action on cancer screening and early detection.
___

Dr. Palmer:
Recently worked for 2 previous high profile executives from GSK.

Dr. Yam:
MD Anderson / GSK long time Cancer Research consortium.

AICS:
MD/GSK collab also focuses on WH cancer inititive.

ViiV Healthcare is 75% owned by GSK.

Dr. Lataillade joined Cytodyn from ViiV.
Last 20 years his focus was HIV.
He oversees our entire Pipeline.
https://www.cytodyn.com/pipeline

Renowned Dr. Palmer is our MASH.
Renowned Dr. Yam is our TNBC.

Reporting to Dr. Lataillade.














(7)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site